Intesa Sanpaolo grants €50 million loan to Autotorino for expansion and sustainability

Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo Wikipedia
Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo - Wikipedia
0Comments

Intesa Sanpaolo has provided €50 million in financing to Autotorino, a leading automotive distribution group in Italy, to support the company’s plans for sustainable growth. The funds will be used for investments aimed at expanding internationally, improving employee welfare and training, and strengthening the sales network. Part of the investment includes acquiring a building in Via Grosio, Milan.

This initiative is part of Intesa Sanpaolo’s broader strategy to back small and medium-sized enterprises (SMEs) through its Banca dei Territori Division. In the first half of 2025, more than €1.1 billion was allocated by the Lombardy North Regional Office for SME investments in Bergamo, Como, Lecco, Sondrio and Varese.

Autotorino, founded in 1965 and marking its 60th anniversary this year, operates across Lombardy, Piedmont, Friuli-Venezia Giulia, Veneto, Emilia-Romagna and Lazio. The company reported sales of about 73,000 vehicles—both new and used—in 2024 with a turnover exceeding €2.6 billion. Over recent years it has achieved several milestones: becoming Italy’s top dealer in 2015; entering the top 50 European Dealers in the ICDP Guide to Europe’s Biggest Dealer Groups in 2017; and ranking as the only Italian company among Europe’s ‘Top 30’ dealers by placing 28th in 2024.

Stefano Martinalli, General Manager and CFO of Autotorino said: “The 2025-2029 business development plan is hinged on three pillars: the consolidation of the distribution network in Italy with the existing brand portfolio, the growth in new foreign markets, and the importing of new emerging brands. Intesa Sanpaolo is a banking partner of excellence, whose support confirms the soundness of our development programme. The investment in the historic Milan Motor Village consolidates Autotorino’s presence in the Lombard capital and opens up new market proposals for the mobility of customers in the Milan city”.

Daniele Pastore, Regional Director Lombardy North of Intesa Sanpaolo added: “Intesa Sanpaolo sees the promotion and support of the development of dynamic companies like Autotorino as truly essential, a driver enabling us to create value for the real and social economy of the communities in which we operate. We are committed, day in, day out, to supporting local companies in their investments in internationalisation, innovation and sustainability. During the first half of this year we disbursed €1.1 billion for growth and development projects for SMEs in the provinces of Bergamo, Como, Lecco, Sondrio and Varese”.

Autotorino employs over 3,000 people across its network of 70 branches located throughout six regions—Piedmont, Lombardy, Emilia-Romagna, Friuli-Venezia Giulia,V eneto and Lazio—and represents eleven automotive groups. The company started operating its first foreign acquisition with a Mercedes-Benz branch based in Warsaw as of January 2025.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.